<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="932">
  <stage>Registered</stage>
  <submitdate>8/12/2005</submitdate>
  <approvaldate>9/12/2005</approvaldate>
  <actrnumber>ACTRN12605000784617</actrnumber>
  <trial_identification>
    <studytitle>A Phase IIIB Multi-Center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate</studytitle>
    <scientifictitle>A Phase IIIB Multi-Center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate</scientifictitle>
    <utrn />
    <trialacronym>IM101-023</trialacronym>
    <secondaryid>Bristol Myers Squibb: IM101-023</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis (RA)</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Drug: Abatacept plus methotrexate for the first 12 months. Month 12 to 24, subjects previously treated with Abatacept plus methotrexate remain on this same treatment. 
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study</interventions>
    <comparator>Drug: Placebo plus methotrexate for the first 12 months. Month 12 to 24 subjects previously dosed with placebo plus methotrexate change to Abatacept plus methotrexate.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The proportion of subjects who achieve remission in 12 months of treatment as defined by a DAS 28 score less that 2.6.</outcome>
      <timepoint>On day 365.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Joint damage progression measured by radiographic evaluation using the Genant√¢ Modified Sharp total score</outcome>
      <timepoint>At 12 months of treatment (Day 365).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the proportion of subjects with an ACR50 response.</outcome>
      <timepoint>At month 12 (Day 365).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the proportion of subjects achieving major clinical response defined by 6 months of consecutive ACR 70 response.</outcome>
      <timepoint>At month 12 (Day 365).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the disease activity as measured by DAS 28 score.</outcome>
      <timepoint>At month 12 (Day 365).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the improvement in physical function using the HAQ disability index.</outcome>
      <timepoint>At month 12 (Day 365) and assess the improvement in physical function at month 24 (Day 729).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the improvement in health-related quality of life using SF-36.</outcome>
      <timepoint>At month 12 (Day 365).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the inhibition of joint damage progression measured by radiographic evaluation using the Genant-modified Sharp erosion, and joint space narrowing.</outcome>
      <timepoint>At month 12 (Day 365).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the inhibition of joint damage progression measured by radiographic evaluation using the Genant-modified Sharp erosion, joint space narrowing and total score.</outcome>
      <timepoint>At month 24 (Day 729).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine the safety and tolerability of abatacept in this subject population, including evaluation of immunogenicity of abatacept.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of rheumatoid arthritis (RA) &lt;2 years; never received treatment with methotrexate; erosions noted on x-ray. CRP &gt;= 8.0 mg/L Rheumatoid factor or anti CCP positive.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Women and men who are not willing to use birth control Diagnosed with other rheumatic disease History of cancer within 5 years Active tuberculosis Treatment with another investigation drug within 28 days Active bacterial or viral infection.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Treatment allocated through central randomisation system by phone and fax</concealment>
    <sequence>Computer generated to randomly allocate treatment</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures>Parallel design followed by crossover design for placebo only.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bristol-Myers Squibb Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cabrini Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cairns Rheumatology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Geoff Littlejohn</name>
      <address>Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+61 3 95943565</phone>
      <fax>+61 3 95946512</fax>
      <email>g.littlejohn@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Geoff Littlejohn</name>
      <address>Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+61 3 95943565</phone>
      <fax>+61 3 95946512</fax>
      <email>g.littlejohn@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>